Xilio initiates Phase 1 combo trial of XTX101 with atezolizumab; reports updated monotherapy data with 33% DCR

Xilio Therapeutics, Inc.

Initiated enrollment for Phase 1 dose escalation of XTX101 in combination with atezolizumab; RP2D for combo expected Q2 2024.
Updated monotherapy data at RP2D (150 mg Q6W) show 33% disease control rate in late-line/IO refractory patients; no discontinuations due to TRAE.
Confirmed partial response in PD-L1 negative NSCLC patient continued through 36 weeks with complete resolution of liver metastases.
Plans to initiate Phase 2 trial in MSS CRC in Q3 2024, subject to obtaining sufficient additional capital.
Preliminary PK demonstrates tumor-selective activation: 96% in melanoma, 73% in liver metastasis vs 13% peripheral activation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.